Live feed06:30:00·901dPRReleasevia QuantisnowAgios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-ThalassemiaByQuantisnow·Wall Street's wire, on your screen.AGIO· Agios Pharmaceuticals Inc.Health Care
